COGT

Cogent Biosciences, Inc. (COGT) | Rumor.io

Cogent Biosciences

COGT

Attention (50-day avg)0%

Attention rank (50-day avg)#964

Bullish sentiment (50-day avg)79%

Price to earnings ratio-15.6

Market capitalization5.5B

Earnings per share-2.16

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-328.9M

Social

What share of all stock conversation is about COGT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% +0

Jun 12

Bezuclastinib, Cogent Biosciences' treatment for advanced systemic mastocytosis, demonstrated significant clinical benefit with a 65% objective response rate and 79% 12-month progression-free survival rate.
The treatment also showed a powerful effect on mast cell burden, with 91% of patients experiencing a reduction in mast cell count.
Cogent Biosciences' presentation of the APEX pivotal trial data at the European Hematology Association (EHA) Congress was seen as a positive catalyst for the company, with potential for commercial adoption exceeding current expectations.

Generated by AI

Sentiment

Of the messages about COGT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +54.44	79.09% -10.78	78.64% -17.18
Bearish	0% 0	0% -54.44	20.91% +10.78	21.36% +17.18

Bullish· Nov 10

$COGT has a strong potential for growth, with a 110% increase to $31 after a successful phase 3 win in the GIST trial.
The stock has a low float and is heavily owned by institutions, which could lead to a significant increase in price, potentially reaching $50-$55.
The stock's short interest is high, with 16 million shares shorted, which could lead to a short squeeze and further price appreciation.

Bearish· Nov 10

The company's shares outstanding have nearly doubled in 3 years, with potentially 20-25M more shares hitting the market, which could dilute each share's value.
The capital structure of the company may be getting heavy due to frequent financing rounds, which could impact the per-share value.
The market may be overvaluing the company, with some investors considering it overpriced and others predicting a drop in price.

Generated by AI

Topics

Of the messages about COGT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	86.38%
Technical Analysis	—	0%	0%	5.84%
Earnings	—	0%	0%	0.76%
Analysts	—	0%	0%	6.6%
Controversies	—	0%	0%	0.07%
Macro	—	0%	0%	0.35%

Earnings· Mar 14

Cogent Biosciences, Inc. reported $59.2M in Q4 revenue, missing the estimated $65.7M.
The company's FY17 revenue of $220M fell short of the estimated $226M.
The discrepancy between revenue and earnings is puzzling, with the company generating over $200 million in annual revenue but not reporting positive earnings.

Announcements· Mar 20

Cogent Biosciences, Inc. (COGT) has seen significant growth in quarterly throughput, exceeding 7 million gallons.
The company has also achieved substantial revenue of over $65 million, with improvements in margins through operational optimization.
Cogent Biosciences, Inc. (COGT) is mentioned alongside Almaden Minerals Ltd. (ALM) in a post discussing growth and execution in the industry.

Generated by AI

Community

Of the messages about COGT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	95.65%	76.11%	88.99%	59.72%
Newcomers	4.35%	23.89%	11.01%	40.28%

Regulars· Jul 7

The SUMMIT trial of Bezuclastinib in patients with non-advanced systemic mastocytosis achieved positive, statistically significant results across all endpoints, including symptom reduction and mast cell burden.
Cogent Biosciences plans to submit a New Drug Application (NDA) to the FDA by the end of 2025, following the trial's successful outcome.
Bezuclastinib demonstrated a good safety profile in the SUMMIT trial, paving the way for potential FDA approval and commercialization.

Newcomers· Mar 20

Cogent Biosciences' revenue and margins are being closely watched by investors, with some noting the company's scaling efforts and optimization strategies.
The quarterly throughput of 7 million gallons is seen as a key metric for the company's growth and execution, with some newcomers to the stock discussing its alignment with operational improvements.
The stock's performance is being compared to other companies in the industry, such as NXXT, with some noting similarities in growth and execution strategies.

Generated by AI

Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s valuation stacks up against the company’s book value. Over the past 5 years the stock is up about 2.7x. This puts real pressure on the question of whether the current price is still in line with what its...

5d agoYahoo Finance

Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased recently, with the 30 day share price return down 13.3% and the 90 day share price return down 17.4%. However, the 1 year total shareholder return of 137.1% suggests earlier optimism around its broader...

5d agoYahoo Finance

Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?

Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal APEX trial data showing clinically meaningful responses and durable clinical activity in Advanced Systemic Mastocytosis, while parallel NDA reviews in NonAdvanced SM and GIST point to a broader...

6d agoYahoo Finance

Cogent Biosciences: A Closer Look At Bezuclastinib And Its Long-Term Potential (NASDAQ:COGT)

6d agoSeeking Alpha

Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

12d agoBenzinga

Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ)

14d agoSeeking Alpha

Also Discussed

Investors talking about COGT also mention

#	Name	Attention
1	Mineralys Therapeutics, Inc.MLYS	0%+0
2	BPMC - Blueprint Medicines Corporation	——
3	Red Violet, Inc.RDVT	0%0
4	Fluent Inc.FLNT	0%new
5	Neurogene Inc.NGNE	0%0
6	BG Staffing IncBGSF	0%new
7	Palvella Therapeutics, Inc.PVLA	0%new
8	Flexible Solutions International Inc.FSI	0%0
9	Mega Matrix Inc.MPU	0%0
10	AIFU Inc. Class A Ordinary ShareAIFU	0%+0

Cogent Biosciences, Inc.

Healthcare
Biotechnology

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its current programs center on targeted small-molecule medicines designed to address specific molecular drivers of serious conditions, with a lead emphasis on KIT-mutated diseases such as systemic mastocytosis and certain gastrointestinal stromal tumors. The company is also advancing additional research programs across other genetically driven cancers and rare diseases, including areas involving FGFR, ErbB2, PI3Kα, KRAS, and JAK2 alterations. Cogent Biosciences works within the biopharmaceutical and precision oncology markets, where highly selective therapies are used to match treatment to disease biology. Headquartered in Waltham, Massachusetts, Cogent Biosciences concentrates on translating molecular insights into specialized treatment options for patients with unmet medical needs.

Website

Location

275 Wyman Street

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about COGT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% +0

Jun 12

Bezuclastinib, Cogent Biosciences' treatment for advanced systemic mastocytosis, demonstrated significant clinical benefit with a 65% objective response rate and 79% 12-month progression-free survival rate.
The treatment also showed a powerful effect on mast cell burden, with 91% of patients experiencing a reduction in mast cell count.
Cogent Biosciences' presentation of the APEX pivotal trial data at the European Hematology Association (EHA) Congress was seen as a positive catalyst for the company, with potential for commercial adoption exceeding current expectations.

Generated by AI

Sentiment

Of the messages about COGT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +54.44	79.09% -10.78	78.64% -17.18
Bearish	0% 0	0% -54.44	20.91% +10.78	21.36% +17.18

Bullish· Nov 10

$COGT has a strong potential for growth, with a 110% increase to $31 after a successful phase 3 win in the GIST trial.
The stock has a low float and is heavily owned by institutions, which could lead to a significant increase in price, potentially reaching $50-$55.
The stock's short interest is high, with 16 million shares shorted, which could lead to a short squeeze and further price appreciation.

Bearish· Nov 10

The company's shares outstanding have nearly doubled in 3 years, with potentially 20-25M more shares hitting the market, which could dilute each share's value.
The capital structure of the company may be getting heavy due to frequent financing rounds, which could impact the per-share value.
The market may be overvaluing the company, with some investors considering it overpriced and others predicting a drop in price.

Generated by AI

Topics

Of the messages about COGT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	86.38%
Technical Analysis	—	0%	0%	5.84%
Earnings	—	0%	0%	0.76%
Analysts	—	0%	0%	6.6%
Controversies	—	0%	0%	0.07%
Macro	—	0%	0%	0.35%

Earnings· Mar 14

Cogent Biosciences, Inc. reported $59.2M in Q4 revenue, missing the estimated $65.7M.
The company's FY17 revenue of $220M fell short of the estimated $226M.
The discrepancy between revenue and earnings is puzzling, with the company generating over $200 million in annual revenue but not reporting positive earnings.

Announcements· Mar 20

Cogent Biosciences, Inc. (COGT) has seen significant growth in quarterly throughput, exceeding 7 million gallons.
The company has also achieved substantial revenue of over $65 million, with improvements in margins through operational optimization.
Cogent Biosciences, Inc. (COGT) is mentioned alongside Almaden Minerals Ltd. (ALM) in a post discussing growth and execution in the industry.

Generated by AI

Community

Of the messages about COGT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	95.65%	76.11%	88.99%	59.72%
Newcomers	4.35%	23.89%	11.01%	40.28%

Regulars· Jul 7

The SUMMIT trial of Bezuclastinib in patients with non-advanced systemic mastocytosis achieved positive, statistically significant results across all endpoints, including symptom reduction and mast cell burden.
Cogent Biosciences plans to submit a New Drug Application (NDA) to the FDA by the end of 2025, following the trial's successful outcome.
Bezuclastinib demonstrated a good safety profile in the SUMMIT trial, paving the way for potential FDA approval and commercialization.

Newcomers· Mar 20

Cogent Biosciences' revenue and margins are being closely watched by investors, with some noting the company's scaling efforts and optimization strategies.
The quarterly throughput of 7 million gallons is seen as a key metric for the company's growth and execution, with some newcomers to the stock discussing its alignment with operational improvements.
The stock's performance is being compared to other companies in the industry, such as NXXT, with some noting similarities in growth and execution strategies.

Generated by AI

Cogent Biosciences

Social

Jun 12

Bullish· Nov 10

Bearish· Nov 10

Earnings· Mar 14

Announcements· Mar 20

Regulars· Jul 7

Newcomers· Mar 20

Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA

Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?

Cogent Biosciences: A Closer Look At Bezuclastinib And Its Long-Term Potential (NASDAQ:COGT)

Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ)

Also Discussed

Cogent Biosciences, Inc.

Company Information

Location

Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA

Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?

Cogent Biosciences: A Closer Look At Bezuclastinib And Its Long-Term Potential (NASDAQ:COGT)

Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ)

Also Discussed

Social

Jun 12

Bullish· Nov 10

Bearish· Nov 10

Earnings· Mar 14

Announcements· Mar 20

Regulars· Jul 7

Newcomers· Mar 20